Aevi Genomic Medicine Announces Completion of Enrollment in Part A of Phase 2 ASCEND Trial in ADHD
Aevi Genomic Medicine Reports Second Quarter 2018 Financial Results and Provides Business Update
Aevi Genomic Medicine, Inc. Announces Novel Co-crystal Version of AEVI-001
Leaders in genetic science and commercial drug development
Discover the future of novel genetic therapies currently being researched by Aevi Genomic Medicine.
Presentations, information, and news